Introducing LIXIANA® (edoxaban): an oral, once-daily, direct factor Xa inhibitor

Lixiana Exodan Doctor

Therapeutic Indications

Nonvalvular atrial fibrillation (NVAF)

  • Prevention of stroke and systemic embolism in eligible adult patients with nonvalvular atrial fibrillation

Venous thromboembolism (VTE)

  • Treatment of deep vein thrombosis (DVT)*

  • Treatment of pulmonary embolism (PE)*

  • Prevention of recurrent DVT and PE following initial treatment for DVT and/or PE

Dossing Icon

Easy to dose

The same once-daily dosing recommendation for both NVAF and VTE indications with proven efficacy.6


Efficay Icon

Efficacy and safety data

Comparable efficacy and superiority in primary safety endpoints vs warfarin in nonvalvular atrial fibrillation and VTE pivotal trials.1,2

People Icon

Appropriate patients

LIXIANA® (edoxaban) has multiple indications and was studied in a broad range of eligible NVAF and VTE patients.6

Clinical Icon

Clinical trial designs

Robust clinical trials designed to study a broad range of patients.1,2


Patient Consultation Icon

Patient consultation resources

Downloadable tools to facilitate dialogue and help patients better understand their disease and treatment.

Folder Icon

Physician resources

Downloadable resources to help you in your practice and reminders to ensure you are up-to-date with the latest news and events.

Indications and Summary of Product Characteristics

Indications and Summary of Product Characteristics

LIXIANA® (edoxaban) is approved for patients with nonvalvular aFib (NVAF) and venous thromboembolism.

Contraindication and Drug Interactions

Dosing

Dosing

LIXIANA® (edoxaban) is easy to dose-the same once-daily dosing across NVAF and VTE indications with proven efficacy6

Appropiate
Patients

Appropriate Patients for LIXIANA® (edoxaban)

Learn more about the multiple indications for LIXIANA® (edoxaban) and the types of patients studied in clinical trials.

Patient Consultation Resources

Download tools

to encourage dialogue and help patients better understand their disease

Physician
Resources

Downloadable resources

to help you in your practice and reminders to ensure you are up to date with the latest news and events.

Efficacy and Safety

Efficacy and Safety

Effective prevention of stroke and VTE and superiority vs warfarin for primary safety endpoints (major bleeding* in NVAF; composite of major* and clinically relevant nonnmajor§ bleeding) in clinical trials.1,2

Clinical Trials

ENGAGE AF-TIMI 48 is the largest and longest comparative trial for stroke prevention in aFib to date.1,3

Hokusai-VTE is the largest single venous thromboembolism trial to date.2,4

  • *

    Following initial use of parenteral anticoagulant for at least 5 days.

  • §

    Major bleeding in nonsurgical patients was defined as5

    1. Fatal bleeding, and/or
    2. Symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome, and/or
    3. Bleeding causing a fall in haemoglobin level of 20 g/L-1 (1.24 mml/L-1) or more, or leading to transfusing of 2 or more units of whole blood or red cells.
  • Clinically relevant nonmajor bleeding was defined as overt bleeding not meeting the criteria for major bleeding§ but associated with medical intervention, unscheduled contact (visit or telephone call) with a physician, (temporary) cessation of study treatment, or leading with any other discomfort such as pain, or impairment of activities of daily life.2

  • Such as cyclosporine, dronedarone, ketoconazole, erythromycin.